What is StimOxyGen?
StimOxyGen operates at the intersection of biotechnology and oncology, specializing in the development of pH-sensitive nanoparticle formulations designed to mitigate hypoxia in solid tumors. By generating molecular oxygen directly within the tumor microenvironment, the company's therapeutic systems significantly enhance the efficacy of conventional cancer treatments, including radiotherapy and chemotherapy. This innovative approach addresses a major clinical bottleneck, as hypoxic conditions often render tumors resistant to standard interventions. Through strategic collaborations with academic institutions like Ulster University, StimOxyGen is effectively bridging the gap between laboratory research and real-world clinical application, positioning itself as a key player in the next generation of precision cancer care.
How much funding has StimOxyGen raised?
StimOxyGen has raised a total of $1.9M across 1 funding round:
Other Financing Round
$1.9M
Other Financing Round (2025): $1.9M with participation from Innovate UK Business Connect, DSW Ventures, QUBIS, and Clarendon Fund Managers
Key Investors in StimOxyGen
Innovate UK Business Connect
Innovate UK Business Connect serves as a vital link for innovators, connecting them with strategic partners and opportunities to accelerate the development of ambitious, real-world solutions.
DSW Ventures
DSW Ventures is a UK-based early-stage venture capital firm that provides hands-on support and equity financing to regional startups across the software, spin-out, and consumer sectors.
QUBIS
QUBIS Ltd specializes in commercializing high-quality academic research from Queens University, Belfast, by providing startup support and enterprise programs to foster life science and technology spinoffs.
What's next for StimOxyGen?
The recent capital injection provides StimOxyGen with the necessary runway to transition from early-stage development toward more advanced clinical validation. Moving forward, the company is expected to prioritize the optimization of its nanoparticle delivery systems and expand its collaborative research efforts to broaden the therapeutic scope of its technology. As the firm scales its operations, the focus will likely shift toward regulatory milestones and potential partnerships with larger pharmaceutical entities, aiming to integrate its oxygen-generating solutions into standard-of-care protocols for patients with resilient, hard-to-treat tumors. This strategic growth trajectory is supported by a robust network of regional and specialized investors committed to fostering high-impact life science innovation.
See full StimOxyGen company page
